Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Wei Teng; Ting‑Tsung Chang; Hwai‑I Yang; Cheng‑Yuan Peng; Chien‑Wei Su; Tung‑Hung Su; Tsung‑Hui Hu; Ming‑Lung Yu; Hung‑Chih Yang; Jaw‑Ching Wu

doi:10.1007/s12072-023-10634-6

Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Wei Teng, Ting‑Tsung Chang, Hwai‑I Yang, Cheng‑Yuan Peng, Chien‑Wei Su, Tung‑Hung Su, Tsung‑Hui Hu, Ming‑Lung Yu, Hung‑Chih Yang, Jaw‑Ching Wu^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Abstract

Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.

Original language	English
Pages (from-to)	1066
Number of pages	1
Journal	Hepatology International
Volume	18
Issue number	3
DOIs	https://doi.org/10.1007/s12072-023-10634-6
State	Published - 06 2024
Externally published	Yes

Bibliographical note

Publisher Copyright:
© Asian Pacific Association for the Study of the Liver 2024.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12072-023-10634-6

Cite this

@article{0a55301c660543ffb5d3bd5047acf3ac,

title = "Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines",

abstract = "Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.",

author = "Wei Teng and Ting‑Tsung Chang and Hwai‑I Yang and Cheng‑Yuan Peng and Chien‑Wei Su and Tung‑Hung Su and Tsung‑Hui Hu and Ming‑Lung Yu and Hung‑Chih Yang and Jaw‑Ching Wu",

note = "Publisher Copyright: {\textcopyright} Asian Pacific Association for the Study of the Liver 2024.",

year = "2024",

month = jun,

doi = "10.1007/s12072-023-10634-6",

language = "英语",

volume = "18",

pages = "1066",

journal = "Hepatology International",

issn = "1936-0533",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Correction to

T2 - Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

AU - Teng, Wei

AU - Chang, Ting‑Tsung

AU - Yang, Hwai‑I

AU - Peng, Cheng‑Yuan

AU - Su, Chien‑Wei

AU - Su, Tung‑Hung

AU - Hu, Tsung‑Hui

AU - Yu, Ming‑Lung

AU - Yang, Hung‑Chih

AU - Wu, Jaw‑Ching

PY - 2024/6

Y1 - 2024/6

N2 - Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.

AB - Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85182805291&partnerID=8YFLogxK

U2 - 10.1007/s12072-023-10634-6

DO - 10.1007/s12072-023-10634-6

M3 - 评论/辩论

C2 - 38252366

AN - SCOPUS:85182805291

SN - 1936-0533

VL - 18

SP - 1066

JO - Hepatology International

JF - Hepatology International

IS - 3

ER -

Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this